25P Association between the lung immune prognostic index (LIPI) and durvalumab consolidation outcomes in patients with locally advanced non-small cell lung cancer (NSCLC)

التفاصيل البيبلوغرافية
العنوان:	25P Association between the lung immune prognostic index (LIPI) and durvalumab consolidation outcomes in patients with locally advanced non-small cell lung cancer (NSCLC)
المؤلفون:	Riudavets Melia, M., Auclin, E., Aboubakar Nana, Frank, Ponce Aix, S., Dal Maso, A., Bluthgen, V., Mielgo, X., Mussat, E., Reyes, R., BenÃtez, J., Lupinacci, L., Duchemann, B., de Giglio, A., Bautista, J., Audigier-Valette, C., Scheffler, M., Campayo, M., Besse, B., Planchard, D., Mezquita, L.
المساهمون:	UCL - SSS/DDUV/GECE - GÃ©nÃ©tique cellulaire, UCL - SSS/IREC/PNEU - PÃ´le de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service de pneumologie
المصدر:	Annals of Oncology, Vol. 32, no.Suppl 7, p. S1384 (2021)
بيانات النشر:	Elsevier BV
سنة النشر:	2021
المجموعة:	DIAL@USL-B (Université Saint-Louis, Bruxelles)
مصطلحات موضوعية:	Oncology, Hematology
الوصف:	BACKGROUND : The LIPI, based on pretreatment derived neutrophils/[leukocytes-neutrophils] ratio (dNLR) >3 and lactate dehydrogenase (LDH) >upper limit of normal (ULN), is associated with immune checkpoint inhibitors (ICI) outcomes in advanced non-small cell lung cancer (NSCLC). We aimed to assess if baseline LIPI correlates with durvalumab efficacy after chemoradiotherapy (ChRT) in the locally advanced setting. [.]
نوع الوثيقة:	conference object
اللغة:	English
تدمد:	0923-7534 1569-8041
Relation:	boreal:268031; http://hdl.handle.net/2078.1/268031; urn:ISSN:0923-7534; urn:EISSN:1569-8041
DOI:	10.1016/j.annonc.2021.10.041
الاتاحة:	http://hdl.handle.net/2078.1/268031 https://doi.org/10.1016/j.annonc.2021.10.041
Rights:	info:eu-repo/semantics/openAccess
رقم الانضمام:	edsbas.59E2D404
قاعدة البيانات:	BASE

View record in BASE

Full Text Finder

الوصف
تدمد:	09237534 15698041
DOI:	10.1016/j.annonc.2021.10.041